Ishemik yurak kasalligi bo‘lgan bemorlarda perkuton koronar aralashuvning buyrak funktsiyasiga ta'siri.
Annotatsiya
Taqdiqot materiallari va usullari: Rentgen-kontrastli preparatlar qo‘llanilgan holda, ChKV o‘tkazgan Ishemik yurak kasalligi bo‘lgan bemorlarning ma’lumotlari tahlil qilindi. Bemorlarning buyrak funksiyasi ko‘rsatkichlari, jumladan, serumsiz kreatinin darajasi va glomerulyar filtratsiya tezligi protsedura oldidan va keyin baholandi. Klinik ko‘rsatkichlar, KIN ning tarqalish darajasi va unga bog‘liq xavf omillari tahlil qilindi.
Taqdiqot natijalari: KIN tarqalishi, buyrak funksiyasining boshlang‘ich holati va qo‘shma kasalliklar mavjudligiga qarab o‘zgarib turdi. KIN rivojlanishining asosiy xavf omillari protsedura oldidan yuqori kreatinin darajasi, qandli diabet va qariyalar edi. Gidratatsiya terapiyasining qo‘llanilishi nefropatiya rivojlanishining kamayishiga olib keldi.
Xulosa: ChKV, ayniqsa qo‘shma xavf omillari mavjud bo‘lsa, Ishemik yurak kasalligi bo‘lgan bemorlarda KIN rivojlanish xavfini oshiradi. Protsedura oldidan buyrak funksiyasini sinchiklab baholash va xavfni kamaytirish uchun profilaktik choralarni qo‘llash tavsiya etiladi.
Mualliflar haqida
Adabiyotlar ro'yxati
Avetisov K.S., Fedorov A.A., Novikov I.A., Light and scanning electron microscopy of anterior lens capsule following different capsulorhexis techniques, Vestnik oftal’mologii, 2015, 131, 06, 4– 10, 10.17116/oftalma201513164-10, In Russian: Аветисов К.С., Федоров А.А., Новиков И.А. Световая и сканирующая электронная микроскопия передней капсулы хрусталика после различных методик капсулорексиса. Вестник офтальмологии. 2015;131(6):4-10.
Coyle L.C., Rodriguez A., Jeschke R.E., Acetylcysteine in Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics, Am Heart J, 2006, 151, 05, 1032.e9–1032.e12, 10.1016/j.ahj.2006.02.002.
Budhiraja P., Chen Z., Popovtzer M., Sodium bicarbonate versus normal saline for protection against contrast nephropathy, Ren Fail, 2009, 31, 02, 118–123, 10.1080/08860220802599239.
Jawdeh B.G., Kanso A., Schelling J.R., Evidence-based approach for prevention of radiocontrast-induced nephropathy, J Hosp Med, 2009, 4, 08, 500–506, 10.1002/jhm.484.
Chong E., Poh K.K., Liang, S., Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions, J Interv Cardiol, 2010, 23, 05, 451–459, 10.1111/j.1540-8183.2010.00573.x.
Alyavi B., Uzokov J., Muminov Sh., Kamilova S., Contrast-induced nephropathy in coronary patients, JACC, 2018, 72, 016, 222.
Detrenis S., Meschi M., Bertolini L., Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures?, J Vasc Interv Radiol, 2007, 18, 02, 177–185, 10.1016/j.jvir.2006.11.020.
Cowburn P.J., Patel H., Pipes R.R., Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity, Eur J Heart Fail, 2005, 7, 05, 899–903, 10.1016/j.ejheart.2005.01.015.
Kedrah A.E., Ari E., Alahdab Y., Effect of the direct renin inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat, Kidney Blood Press Res, 2012, 35, 06, 425–430, 10.1159/000338672.
Albabtain M.A., Almasood A., Alshurafah H., Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study, J Interv Cardiol, 2013, 26, 01, 90–96, 10.1111/j.1540- 8183.2012.00700.x.
Gami A.S., Garovic V.D., Contrast nephropathy after coronary angiography, Mayo Clin Proc, 2014, 79, 02, 211–219, 10.4065/79.2.211.
Goldenberg I., Matetzky S., Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies, CMAJ, 2005, 172, 011, 1461–1471, 10.1503/cmaj.1041114.
Gomes V.O., Lasevitch R., Lima V.C., Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial, Arq Bras Cardiol, 2012, 99, 06, 1129–1134, 10.1590/s0066- 782x2012005000107.
Conen D., Buerkle G., Perruchoud A.P., Hypertension is an independent risk factor for con- trast nephropathy after percutaneous coronary intervention, Int J Cardiol, 2006, 110, 02, 237–241, 10.1016/j.ijcard.2005.07.020.
Quintavalle C., Fiore D., De Micco F., Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury, Circulation, 2012, 126, 025, 3008–3016, 10.1161/CIRCULATIONAHA.112.128934.
Jorgensen A.L., Contrast-induced nephropathy: pathophysiology and preventive strategies, Critical Care Nurse, 2013, 33, 01, 37–46, 10.4037/ccn2013782.
Kunadian V., Zaman A., Spyridopoulos I., Qiu W., Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials, European Journal of Radiology, 2011, 79, 01, 48–55, 10.1016/j.ejrad.2010.02.014.
Mehran R., Nikolsky E., Contrast-induced nephropathy: definition, epidemiology, and patients at risk, Kidney International Supplements, 2006, 100, 10.1038/sj.ki.5000368.
Morcos S.K., Thomsen H.S., Webb J.A., Contrast-media-induced nephrotoxicity: a consensus report, European Radiology, 1999, 9, 08, 1602–1613, 10.1007/s003300050897.
Murphy S.W., Barrett J., Parfrey P.S., Contrast nephropathy, Journal of the American Society of Nephrology, 2000, 11, 01, 177–182, 10.1681/ASN.V111177.
Jaipaul N., Manalo R., Sadjadi S.A., Obesity is not associated with contrast nephropathy, Journal of Therapeutic Clinical Risk Management, 2010, 6, 213–217, 10.2147/TCRM.S9088.
Markota D., Markota I., Starcevic B., Prevention of contrast-induced nephropathy with Na/K citrate, European Heart Journal, 2013, 34, 030, 2362–2367, 10.1093/eurheartj/eht187.
Gulel O., Keles T., Eraslan H., Prophylactic acetylcysteine usage for prevention of contrast nephropa- thy after coronary angiography, Journal of Cardiovascular Pharmacology, 2014, 46, 04, 464–467, 10.1097/00005344-201404000-00025.
Drager L.F., Barros de Toledo J.F., Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury, Nephrology Dialysis Transplantation, 2004, 19, 07, 1803–1807, 10.1093/ndt/gfh259
Krusova D., Sevela K., Kralova D., Risky medication and contrast media-induced nephropa- thy in patients with diabetes and hypertension, Vnitrni Lekarstvi, 2014, 52, 011, 1014–1020, 10.36246/01.9201.1277995720.
Tepel M., Aspelin P., Lameire N., Contrast-induced nephropathy: a clinical and evidence-based approach, Circulation, 2006, 113, 014, 1799–1806, 10.1161/CIRCULATIONAHA.105.593210.
Teplan V., Contrast nephropathy and prevention, Vnitr Lek, 2012, 58, 07-8, 553–556.
Oguzhan N., Cilan H., Sipahioglu M., The Lack of Benefit of a Combination of an Angiotensin Receptor Blocker and Calcium Channel Blocker on Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease, Ren Fail, 2013, 35, 04, 434–439, 10.3109/0886022X.2013.775643.
Gare M., Haviv Y.S., Ben A.Yehuda., The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography, J Am Coll Cardiol, 1999, 34, 06, 1682–1688, 10.1016/S0735-1097(99)00404-5.
Mamoulakis C., Tsarouhas K., Fragkiadoulaki I., Contrast-induced nephropathy: Basic concepts, pathophysiological implications, and prevention strategies, Pharmacol Ther, 2017, 180, 99–112, 10.1016/j.pharmthera.2017.06.009.
Copyright (c) 2024 Nodir U. Zakirov, Jamshid B. Irirov, Xusnidin Sh. Kuchkarov, Axtam A. Tolibov.
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution-NonCommercial-ShareAlike» («Atribut - notijorat maqsadlarda foydalanish - bir xil shartlar») 4.0 Всемирная.